after you have joined the study, you will be assigned randomly to receive either the active drug or a matching placebo. the assignment is done by the study team and you will not know which one you receive.

you will be given a bottle containing tablets. each tablet contains 150 mg of crd-4730 if you are in the active group, or a matching placebo tablet if you are in the control group. the tablets are taken by mouth.

you will take one tablet each day, preferably at the same time each day, for a total of 24 weeks. the tablet is swallowed whole with water and should be taken with or without food.

if you experience any side effects, you should record them in the diary provided and inform the study staff at the next visit.

after 12 weeks of taking the tablet, you will return to the clinic for a follow‑up visit. during this visit, blood will be drawn to measure a marker called nt-probnP, and an echocardiogram (ultrasound of the heart) will be performed to check heart size and function.

you will also complete a questionnaire about your heart‑failure symptoms and quality of life. the study staff will check your vital signs, review any side effects, and ensure the medication is being taken as directed.

at the end of 24 weeks, you will attend the final study visit. the same set of tests performed at week 12 will be repeated, including blood tests, echocardiogram, and the symptom questionnaire.

the study team will collect information about any adverse events that occurred during the study and will assess the overall safety and effectiveness of the treatment.

after the final assessments, you will stop taking the study tablet. the study staff will discuss any further care you may need.